Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
- Raajit K. Rampal
- , Sebastian Grosicki
- , Dominik Chraniuk
- , Elisabetta Abruzzese
- , Prithviraj Bose
- , Aaron T. Gerds
- , Alessandro M. Vannucchi
- , Francesca Palandri
- , Sung Eun Lee
- , Vikas Gupta
- , Alessandro Lucchesi
- , Stephen T. Oh
- , Andrew T. Kuykendall
- , Andrea Patriarca
- , Alberto Álvarez-Larrán
- , Ruben Mesa
- , Jean Jacques Kiladjian
- , Moshe Talpaz
- , Joseph M. Scandura
- , David Lavie
- Memorial Sloan-Kettering Cancer Center
- Medical University of Silesia in Katowice
- Hematology Ward
- University of Rome Tor Vergata
- University of Texas MD Anderson Cancer Center
- Cleveland Clinic Foundation
- University of Florence
- Policlinico S. Orsola-Malpighi
- Ontario Cancer Institute
- IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori - Meldola (FC)
- Washington University St. Louis
- Moffitt Cancer Center
- Ospedale Maggiore
- Hospital Clínic i Universitari
- Wake Forest University
- Université Paris Cité
- University of Michigan, Ann Arbor
- Cornell University
- Hadassah University Medical Centre
- Constellation Pharmaceuticals, Inc.
- MorphoSys AG
- Novartis
- Guy's and St Thomas' NHS Foundation Trust
- Icahn School of Medicine at Mount Sinai
Research output: Contribution to journal › Article › peer-review
36
Scopus
citations